TEVA
Teva Pharmaceutical Industries Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Señales de momentum (gestores comparables): amplitud de titulares 0.0% · flujo de acciones -0.2% · nuevas posiciones netas 0.0% · fórmula
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 149 | +7 | 367.15M | $12.41B | +9 | −3 |
| Q1 2026 | 146 | +3 | 327.68M | $9.78B | +10 | −8 |
| Q4 2025 | 144 | -1 | 326.44M | $10.18B | +3 | −3 |
| Q3 2025 | 23 | 0 | 176.53M | $3.56B | +1 | −2 |
| Q2 2025 | 21 | 0 | 197.53M | $3.31B | n/a | n/a |
| Q1 2025 | 18 | -3 | 84.56M | $1.30B | n/a | −3 |
| Q4 2024 | 21 | -1 | 89.79M | $1.98B | n/a | −1 |
| Q3 2024 | 21 | +2 | 78.93M | $1.23B | +2 | n/a |
| Q2 2024 | 19 | n/a | 61.88M | $1.01B | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 58.14M | n/a | $974.35M | 0.1% | n/c | 1 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (pasivo) | 54.32M | n/a | $910.38M | 0.0% | n/c | 1 | SEC ↗ ×20 |
| 3 | State Street Global Advisors ✦ (pasivo) | 17.29M | -0.2% | $289.73M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Duquesne Family Office ✦ | 15.97M | +7.3% | $267.64M | 6.8% | ▲ Add | 4 | SEC ↗ |
| 5 | Glenview Capital ✦ | 15.82M | +7.1% | $265.21M | 7.5% | ▲ Add | 5 | SEC ↗ |
| 6 | Viking Global Investors ✦ | 11.68M | +15.4% | $195.78M | 0.6% | ▲ Add | 4 | SEC ↗ |
| 7 | Geode Capital Management ✦ (pasivo) | 9.63M | +4.7% | $160.25M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Greenlight Capital (DME Capital) ✦ | 3.78M | +565.0% | $63.33M | 2.7% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | Renaissance Technologies ✦ | 3.16M | -40.5% | $52.91M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 2.21M | -22.4% | $37.09M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 11 | Norges Bank ✦ (pasivo) | 1.86M | -27.9% | $31.25M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Millennium Management ✦ | 1.10M | -80.0% | $18.42M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | The Vanguard Group ✦ (pasivo) | 885.45K | n/a | $14.84M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Adage Capital Partners ✦ | 534.00K | +10.3% | $8.95M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 461.12K | +13.7% | $7.73M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 16 | Two Sigma Investments ✦ | 319.89K | +133.8% | $5.36M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 121.82K | +50.1% | $2.04M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 18 | ARK Investment Management ✦ | 120.87K | +33.9% | $2.03M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 19 | GAMCO Investors ✦ | 89.20K | -4.3% | $1.49M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 26.03K | +8.7% | $436,245 | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 21 | Wellington Management ✦ | 17.53K | -87.3% | $293,870 | 0.0% | ▼ Trim | 5 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 646 tenedores, 666.61M acciones, $16.70B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 2.52K acc. · $98,841
Director · 367.60K acc. · $14.36M
Officer · 4.50K acc. · $174,221
Officer · 314 acc. · $12,153
Officer · 2.50K acc. · $94,077
Director · 415 acc. · $15,459
Officer · 6.95K acc. · $261,224
Officer · 18.60K acc. · $680,291
Director · 17 acc. · $593
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología